Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS 1 oral semaglutide 50 mg in adults with overweight or obesity
jRCT2031210297Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, double-blind trial in obesity and Overweight comparing Oral semaglutide 50 mg once daily with Placebo once daily (2 arms). Primary endpoints: Relative change in body weight from baseline to end-of-treatment and Achievement of ≥5% body weight reduction at end-of-treatment. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2031210297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210297.